Texas Capital Bank Wealth Management Services Inc Makes New Investment in AstraZeneca PLC (NASDAQ:AZN)

Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 3,150 shares of the company’s stock, valued at approximately $213,000.

A number of other institutional investors have also recently bought and sold shares of the company. O Shaughnessy Asset Management LLC grew its holdings in AstraZeneca by 17.9% during the first quarter. O Shaughnessy Asset Management LLC now owns 111,659 shares of the company’s stock valued at $7,565,000 after purchasing an additional 16,966 shares during the period. Rockport Wealth LLC bought a new stake in shares of AstraZeneca during the first quarter worth $370,000. Catalytic Wealth RIA LLC increased its position in shares of AstraZeneca by 4.3% during the first quarter. Catalytic Wealth RIA LLC now owns 27,386 shares of the company’s stock worth $1,855,000 after acquiring an additional 1,134 shares in the last quarter. Jacobi Capital Management LLC increased its position in shares of AstraZeneca by 39.2% during the first quarter. Jacobi Capital Management LLC now owns 10,159 shares of the company’s stock worth $688,000 after acquiring an additional 2,860 shares in the last quarter. Finally, TIAA Trust National Association increased its position in shares of AstraZeneca by 7.7% during the first quarter. TIAA Trust National Association now owns 235,599 shares of the company’s stock worth $15,962,000 after acquiring an additional 16,898 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Argus increased their price objective on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, May 30th. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. BMO Capital Markets raised their target price on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Friday, April 26th. Finally, Barclays raised shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $88.00.

AstraZeneca Stock Up 0.0 %

AstraZeneca stock traded up $0.01 during mid-day trading on Tuesday, reaching $79.17. The company’s stock had a trading volume of 2,832,646 shares, compared to its average volume of 5,291,275. The company has a market capitalization of $245.47 billion, a price-to-earnings ratio of 38.56, a price-to-earnings-growth ratio of 1.42 and a beta of 0.45. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $80.86. The business’s 50 day simple moving average is $78.39 and its 200 day simple moving average is $71.68. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.70 and a current ratio of 0.89.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, April 25th. The company reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.08. The firm had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $11.92 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. As a group, research analysts anticipate that AstraZeneca PLC will post 4.05 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.